Newly christened U.K. outsourcer sets sail in the Cambridge biopharma hub

U.K. outsourcers PolyTherics and Antitope have merged to pool their R&D resources, christening the combined company Abzena and targeting the bustling biomedical hub of Cambridge for new headquarters.

CRO Rho mounts a talent search as contracts come in

Rho, a midsize contract researcher out of North Carolina, is looking to expand its footprint to deal with a widening client base, setting out to expand its ranks of investigators and execs.

Medidata teams up with Big Pharma supergroup to derisk trials

Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.

Parexel zeroes in on adaptive trials with its latest eClinical move

As the industry embraces risk-based clinical trial monitoring, Parexel International is expanding its banner eClinical offering to help sponsors make data-driven decisions in the middle of a study.

Covance dials up its postmarket biz with latest buy

Global CRO Covance is looking to expand its share of the drug-commercialization space, buying up a U.K. market access specialist to help its clients sell their approved products.

WuXi wraps up construction on a new biologics shop

China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.

Bayer agrees to share trial data, but not without a list of caveats

Bayer is joining the bandwagon of drugmakers getting in on clinical trial transparency, signing on to share some of its data with researchers but stopping well short of industry trailblazers.

PRA amps up its biologics footprint amid industry shift

Oft-merged CRO giant PRA has expanded its large-molecule capabilities in the U.S., setting up a bioanalysis shop right next to its clinics to make for faster trials.

Evotec's hybrid CRO approach pays off in Q1

Germany's Evotec splits its operation between contract research for big-name third parties and in-house work on its own pipeline, riding its uncommon take on the CRO business to an uptick in revenue last quarter.

WuXi scores more double-digit growth amid its global expansion

Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.

Quintiles targets healthcare providers with its latest buy

Quintiles, the world's largest CRO, is further expanding its outside-the-clinic business, agreeing to buy healthcare analytics outfit Encore Health Resources to beef up its access to real-world patient data.

Icon wraps up its $143.5M deal for Aptiv

Irish CRO Icon has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan.

China's WuXi dials up its R&D presence at home and abroad

WuXi PharmaTech, China's largest CRO, is upping its capacity in its two largest markets, wrapping up an expansion of a U.S. early-stage operation and breaking ground on an R&D campus outside of Shanghai.

China's Tigermed buys a $50M stake in a U.S. CRO

Chinese CRO Tigermed is buying its way into the U.S., signing a deal to trade $50.3 million for a majority stake in Pennsylvania's Frontage Laboratories.

AMRI posts flat revenue as transitional year marches on

Contract drug developer AMRI turned in a stagnant revenue quarter, watching profits slip as it prepares to shake off its dependence on royalties and embrace a future in large-scale manufacturing.

Royalty Pharma backs risk-friendly researcher Avillion

Avillion, a contract researcher that teams up on late-stage drugs in exchange for a cut of profits, has added the complementarily focused Royalty Pharma to its investor syndicate, joining VCs Abingworth and Clarus Ventures.

Huntingdon buys Harlan Labs in a bet on CRO growth

Non-clinical contract researcher Huntingdon Life Sciences has acquired Harlan Laboratories, boosting its stake in animal models and creating a combined company with revenue it says will reach near half a billion dollars a year.

WuXi passes FDA muster in China and amps up its U.S. presence

Chinese outsourcing giant WuXi PharmaTech passed an FDA audit at one of its local facilities and broke ground on a new plant in the U.S., executing on its two-pronged strategy to take a bigger share of the global drug development market.

Covance slips after narrowing its 2014 ambitions

Covance's shares fell as much as 10% after the CRO ​missed its internal sales goals in the first quarter and dialed down its revenue projection for the year.

Charles River ticks up revenue with M&A on tap

Charles River Laboratories posted a slight increase in sales last quarter, crediting a rise in preclinical demand as it counts on some new acquisitions to brighten 2014.